LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Radiation exposure in acute myeloid leukaemia, diffuse large B-cell lymphoma, and multiple myeloma patients in the first year following diagnosis.

    Koluman, Başak Ünver / Arslan, Muhammet / Şenol, Hande / Hacıoğlu, Sibel Kabukçu / Çağlıyan, Gülsüm Akgün / Güler, Nil / Türk, Nilay Şen

    Polish journal of radiology

    2023  Volume 88, Page(s) e75–e79

    Abstract: Purpose: Radiological examinations are critical in the evaluation of patients with haematological malignancies for diagnosis and treatment. Any dose of radiation has been shown in studies to be harmful. In this regard, we assessed the radiation exposure ...

    Abstract Purpose: Radiological examinations are critical in the evaluation of patients with haematological malignancies for diagnosis and treatment. Any dose of radiation has been shown in studies to be harmful. In this regard, we assessed the radiation exposure of 3 types of haematological malignancies (diffuse large B-cell lymphoma [DLBCL], acute myeloid leukaemia [AML], and multiple myeloma [MM]) in our centre during the first year after diagnosis.
    Material and methods: In the first year after diagnosis we retrospectively reviewed the radiation exposure data of 3 types of haematological malignancies (DLBCL, AML, and MM). The total and median CED value (cumulative effective radiation dose in millisieverts [mSv]) of each patient was used. Each patient's total and median estimated CED value was calculated using a web-based calculator and recorded in millisieverts (mSv).
    Results: The total radiation doses in one year after diagnosis (CED value) were 46.54 ± 37.12 (median dose: 36.2) in the AML group; 63.00 ± 42.05 (median dose: 66.4) in the DLBCL group; and 28.04 ± 19.81 (median dose: 26.0) in the MM group (
    Conclusions: In all 3 haematological malignancies, the radiation exposure was significant, especially in the DBLCL group, within the first year of diagnosis. It is critical to seek methods to reduce these dosage levels. In diagnostic radiology, reference values must be established to increase awareness and self-control and reduce patient radiation exposure. This paper is also the first to offer thorough details on the subject at hand, and we think it can serve as a guide for further investigation.
    Language English
    Publishing date 2023-02-03
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2675143-4
    ISSN 1899-0967 ; 1733-134X
    ISSN (online) 1899-0967
    ISSN 1733-134X
    DOI 10.5114/pjr.2023.125008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Serum Hepcidin and Prohepcidin Levels in Nonfebrile and Febrile Neutropenia.

    Koluman, Basak Unver / Avci, Esin / Guler, Nil / Cagliyan, Gulsum Akgun / Senol, Hande

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

    2021  Volume 31, Issue 11, Page(s) 1303–1307

    Abstract: Objective: To compare the prohepcidin and hepcidin levels in the afebrile neutropenic period and neutropenic fever in patients with hematological malignancy.: Study design: Descriptive study.: Place and duration of study: Department of Hematology, ...

    Abstract Objective: To compare the prohepcidin and hepcidin levels in the afebrile neutropenic period and neutropenic fever in patients with hematological malignancy.
    Study design: Descriptive study.
    Place and duration of study: Department of Hematology, Pamukkale University Hospital, Denizli, Turkey, between January 2018 and December 2019.
    Methodology: Neutropenic patients were compared with a healthy control group. Prohepcidin and hepcidin serum levels were to be measured in neutropenic and control groups. When fever occurred in neutropenic group, serum was taken again and the same values were compared, in addition to procalcitonin and CRP values.
    Results: Prohepcidin and hepcidin levels were found to be significantly higher in the neutropenic group (n = 53) than the control group [n = 44, (med:166.65 ng/ml, IQR:147.66 - 187.38 ng/ml vs. med:47.49 ng/ml, IQR:15.61 - 82.51 ng/ml; p <0.001); (med:315 ng/ml, IQR:314.92 - 315 ng/ml vs. med:26.61 ng/ml, IQR:4.69 - 66.83 ng/ml; p <0.001)]. No significant difference was found in terms of these two analyses (167.29 ± 29.31 ng/ml vs. 167.15 ± 27.61 ng/ml; p = 0.979; 296.21 ± 37.19 ng/ml vs 299.16 ± 37.68 ng/ml; p= 0.629) in the neutropenic fever period compared to the afebrile neutropenic period. In neutropenic fever patients, procalcitonin and CRP (C-reactive protein) were found significantly higher than the afebnile neutropenic group (0.7 ± 1.2 ng/ml vs. 0.25 ± 0.76 ng/ml; p = 0.034; 10.27 ± 9.93 mg/dl vs 2.61 ± 2.78 mg/dl; p <0.001).
    Conclusion: Although there was no significant difference between afebnile neutropenia and neutropenic fever in patients in terms of hepcidin and prohepcidin levels, higher levels were found in both groups compared to the control group. Key Words: Hepcidin, Prohepcidin, Neutropenia, Febrile neutropenia.
    MeSH term(s) C-Reactive Protein ; Febrile Neutropenia ; Hepcidins ; Humans ; Procalcitonin ; Protein Precursors
    Chemical Substances Hepcidins ; Procalcitonin ; Protein Precursors ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2021-10-23
    Publishing country Pakistan
    Document type Journal Article
    ZDB-ID 2276646-7
    ISSN 1681-7168 ; 1022-386X
    ISSN (online) 1681-7168
    ISSN 1022-386X
    DOI 10.29271/jcpsp.2021.11.1303
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

    Gemici, Aliihsan / Ozkalemkas, Fahir / Dogu, Mehmet Hilmi / Tekinalp, Atakan / Alacacioglu, Inci / Guney, Tekin / Ince, Idris / Geduk, Ayfer / Cagliyan, Gulsum Akgun / Maral, Senem / Serin, Istemi / Gunduz, Eren / Karakus, Volkan / Bekoz, Huseyin Saffet / Eren, Rafet / Pinar, Ibrahim Ethem / Gunes, Ahmet Kursad / Sargın, Fatma Deniz / Sevindik, Omur Gokmen

    Clinical lymphoma, myeloma & leukemia

    2021  Volume 21, Issue 8, Page(s) e686–e692

    Abstract: Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose ... ...

    Abstract Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML.
    Materials and methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML.
    Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported.
    Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Female ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/mortality ; Remission Induction ; Sulfonamides/therapeutic use ; Survival Analysis ; Treatment Outcome ; Turkey
    Chemical Substances Antineoplastic Agents ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2021-04-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2021.04.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Splanchnic vein thrombosis following renal transplantation: a case report.

    Tatar, Erhan / Uslu, Adam / Aykas, Ahmet / Tasli, Funda / Oztekin, Ozgur / Cagliyan, Gulsum Akgun

    BMC nephrology

    2013  Volume 14, Page(s) 161

    Abstract: Background: Recurrent episodes of venous thrombosis have been closely correlated with JAK2 V617F mutation. Upto date, JAK2 gene mutation has not been defined as a prothrombic risk factor in renal transplant recipients. Herein; we present a case of ... ...

    Abstract Background: Recurrent episodes of venous thrombosis have been closely correlated with JAK2 V617F mutation. Upto date, JAK2 gene mutation has not been defined as a prothrombic risk factor in renal transplant recipients. Herein; we present a case of portosplenic vein thrombosis in a primary renal transplant recipient with JAK2 V617F mutation who had no history of prior venous thromboembolism or thrombophilia.
    Case presentation: A 59 year old female caucasian patient with primary kidney transplant admitted with vague abdominal pain at left upper quadrant. Abdominal doppler ultrasound and magnetic resonance imaging angiography demonstrated splanchnic vein thrombosis (SVT). The final diagnosis was SVT due to MPD (essential thrombocytosis, ET) with JAK2 V617F mutation. After 3 months of treatment with warfarin (≥5 mg/day, to keep target INR values of 1.9-2.5), control MRI angiography and doppler USG demonstrated partial (>%50) resolution of thrombosis with recanalization of hepatopedal venous flow. The patient is still on the same treatment protocol without any complication.
    Conclusion: JAK2 V617F mutation analysis should be a routine procedure in the diagnosis and treatment of kidney transplant patients with thrombosis in uncommon sites.
    MeSH term(s) Female ; Humans ; Kidney Transplantation/adverse effects ; Middle Aged ; Postoperative Complications ; Splanchnic Circulation/physiology ; Venous Thrombosis/diagnosis ; Venous Thrombosis/etiology
    Language English
    Publishing date 2013-07-22
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2041348-8
    ISSN 1471-2369 ; 1471-2369
    ISSN (online) 1471-2369
    ISSN 1471-2369
    DOI 10.1186/1471-2369-14-161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report.

    Ozatli, Duzgun / Giden, Aslı Odabaşı / Erkurt, Mehmet Ali / Korkmaz, Serdal / Basci, Semih / Ulas, Turgay / Turgut, Burhan / Yigenoglu, Tugce Nur / Hacibekiroglu, Tuba / Basturk, Abdulkadir / Dal, Mehmet Sinan / Namdaroglu, Sinem / Hindilerden, Fehmi / Hacioglu, Sibel Kabukcu / Cagliyan, Gulsum Akgun / Ilhan, Gul / Kacmaz, Murat / Uysal, Ayşe / Merter, Mustafa /
    Ekinci, Omer / Dursun, Fadime Ersoy / Tekinalp, Atakan / Demircioglu, Sinan / Sincan, Gulden / Acik, Didar Yanardag / Akdeniz, Aydan / Ucar, Mehmet Ali / Yeral, Mahmut / Ciftciler, Rafiye / Teke, Hava Uskudar / Umit, Elif Gulsum / Karakus, Abdullah / Bilen, Yusuf / Yokus, Osman / Albayrak, Murat / Demir, Cengiz / Okan, Vahap / Serefhanoglu, Songül / Kartı, Sami / Ozkurt, Zubeyde Nur / Eser, Bulent / Aydogdu, Ismet / Kuku, Irfan / Cagirgan, Seckin / Sonmez, Mehmet / Ozet, Gulsum / Altuntas, Fevzi

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2023  Volume 62, Issue 2, Page(s) 103662

    Abstract: Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has ... ...

    Abstract Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.
    MeSH term(s) Humans ; Turkey ; Blood Component Removal/methods ; Registries ; Databases, Factual
    Language English
    Publishing date 2023-02-24
    Publishing country England
    Document type Consensus Development Conference ; Journal Article ; Review
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2023.103662
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.

    Akpinar, Seval / Dogu, Mehmet Hilmi / Celik, Serhat / Ekinci, Omer / Hindilerden, Ipek Yonal / Dal, Mehmet Sinan / Davulcu, Eren Arslan / Tekinalp, Atakan / Hindilerden, Fehmi / Ozcan, Busra Gokce / Hacibekiroglu, Tuba / Erkurt, Mehmet Ali / Bagci, Metin / Namdaroglu, Sinem / Korkmaz, Gulten / Bilgir, Oktay / Cagliyan, Gulsum Akgun / Ozturk, Hacer Berna Afacan / Serin, Istemi /
    Tiryaki, Tarık Onur / Ozatli, Duzgun / Korkmaz, Serdal / Ulas, Turgay / Eser, Bulent / Turgut, Burhan / Altuntas, Fevzi

    Clinical lymphoma, myeloma & leukemia

    2021  Volume 22, Issue 3, Page(s) 169–173

    Abstract: Introduction/background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL ... ...

    Abstract Introduction/background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings.
    Patients/methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers.
    Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p
    Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.
    MeSH term(s) Adenine/analogs & derivatives ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Neoplasm Recurrence, Local/drug therapy ; Piperidines ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Retrospective Studies
    Chemical Substances Piperidines ; Pyrazoles ; Pyrimidines ; ibrutinib (1X70OSD4VX) ; Adenine (JAC85A2161)
    Language English
    Publishing date 2021-09-15
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2021.09.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience.

    Gemici, Aliihsan / Aydogdu, Ismet / Terzi, Hatice / Sencan, Mehmet / Aslan, Alma / Kaya, Ali Hakan / Dal, Mehmet Sinan / Akay, Meltem Olga / Dogu, Mehmet Hilmi / Ayyildiz, Orhan / Sahin, Fahri / Cagliyan, Gulsum Akgun / Yilmaz, Mehmet / Gokgoz, Zafer / Bilen, Yusuf / Demir, Cengiz / Sevindik, Omur Gokmen / Korkmaz, Serdal / Eser, Bulent /
    Altuntas, Fevzi

    Hematological oncology

    2017  

    Abstract: Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in ... ...

    Abstract Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5 years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46 months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.
    Language English
    Publishing date 2017-07-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2460
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top